OBJECTIVE AND DESIGN: This double-blind cross-over study compared the potential of bilastine, cetirizine, and fexofenadine to relieve the symptoms of allergic rhinitis. SUBJECTS AND METHODS: Seventy-five allergic volunteers were challenged with grass pollen in the Vienna Challenge Chamber (VCC) on two consecutive days of allergen provocation; 6 h on day 1 and 4 h day 2. Bilastine 20 mg, cetirizine 10 mg, fexofenadine 120 mg, or placebo were taken orally 2 h after the start of provocation on day 1 only. Total nasal symptom scores, the global symptom scores, nasal secretions, and eye symptoms were assessed on both day 1 and day 2. RESULTS AND CONCLUSIONS:Bilastine had a rapid onset of action, within 1 h, and a long duration of action, greater than 26 h. Cetirizine was similar. Fexofenadine was similar on day 1 but less effective on day 2, indicating a shorter duration of action. Bilastine, like cetirizine and fexofenadine, was safe and well tolerated in this study.
RCT Entities:
OBJECTIVE AND DESIGN: This double-blind cross-over study compared the potential of bilastine, cetirizine, and fexofenadine to relieve the symptoms of allergic rhinitis. SUBJECTS AND METHODS: Seventy-five allergic volunteers were challenged with grass pollen in the Vienna Challenge Chamber (VCC) on two consecutive days of allergen provocation; 6 h on day 1 and 4 h day 2. Bilastine 20 mg, cetirizine 10 mg, fexofenadine 120 mg, or placebo were taken orally 2 h after the start of provocation on day 1 only. Total nasal symptom scores, the global symptom scores, nasal secretions, and eye symptoms were assessed on both day 1 and day 2. RESULTS AND CONCLUSIONS:Bilastine had a rapid onset of action, within 1 h, and a long duration of action, greater than 26 h. Cetirizine was similar. Fexofenadine was similar on day 1 but less effective on day 2, indicating a shorter duration of action. Bilastine, like cetirizine and fexofenadine, was safe and well tolerated in this study.
Authors: G Walter Canonica; Jean Bousquet; Geneviève Van Hammée; Claus Bachert; Stephen R Durham; Ludger Klimek; Joaquim Mullol; Paul B Van Cauwenberge Journal: Respir Med Date: 2006-05-24 Impact factor: 3.415
Authors: F Horak; P Stübner; R Zieglmayer; A Kavina; C De Vos; B Burtin; F Donnelly Journal: Int Arch Allergy Immunol Date: 2001-05 Impact factor: 2.749
Authors: Xianbin Tian; Maciej J Zamek-Gliszczynski; Jun Li; Arlene S Bridges; Ken-ichi Nezasa; Nita J Patel; Thomas J Raub; Kim L R Brouwer Journal: Drug Metab Dispos Date: 2007-10-03 Impact factor: 3.922
Authors: Claus Graff; Johannes J Struijk; Jørgen K Kanters; Mads P Andersen; Egon Toft; Benoît Tyl Journal: Clin Drug Investig Date: 2012-05-01 Impact factor: 2.859
Authors: Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana Journal: Ocul Surf Date: 2021-05-15 Impact factor: 6.268